ERBB2 and breast carcinoma: These results indicated that tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN can be biomarkers and novel therapeutic targets for HER-2 positive breast cancer patients with trastuzumab resistance.